Gianluca Piccolo1,2*
Elena Lucia De Rose1
Marta Bassi1,3
Flavia Napoli3
Nicola Minuto3,4
Mohamad Maghnie1,3
Giuseppa Patti1,3*
Giuseppe d’Annunzio3,4- 1Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy
- 2Neuro-oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 3Pediatric Clinic and Endocrinology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 4Pediatric Clinic and Endocrinology Unit, Regional Center for Pediatric Diabetes, IRCCS Istituto Giannina Gaslini, Genoa, Italy
Diabetes mellitus (DM) has been frequently associated with an impaired immune response against infectious agents, making affected patients at risk for more severe disease and sometimes causing worse outcomes. The recent COVID-19 pandemic has seriously affected patients with both diabetes, in particular those carrying comorbidities or with poor glycemic control. As regards pediatric diabetes mellitus, the availability of more accurate and technological tools for glycemic management and the improved markers of metabolic control might mitigate the negative impact of infections. Notably, good metabolic control of diabetes since its diagnosis reduces not only the risk of microangiopathic complications but also of impaired immune response to infectious diseases. Therefore, vaccinations are strongly recommended. Our paper aims to provide the most updated evidence regarding infectious diseases in type 1 pediatric DM.
1 Introduction
Type 1 diabetes mellitus (T1DM), arising from a complex interaction between immune, genetic and environmental factors, results from autoimmune-mediated destruction of insulin-producing pancreatic β-cells in genetically predisposed individuals (1). Even if the causative mechanisms are not yet completely defined, T1DM incidence is increasing worldwide (2). Several studies showed that genetic susceptibility alone does not explain the development of the disease and suggested that environmental factors play an important etiopathogenetic role (3). Among environmental factors, the most frequently studied include feeding, infections, gut microbiota, perinatal, and social factors (4, 5). On the other hand, some evidence suggests that lack of exposure in early life to viruses or other infectious agents could increase the risk of T1DM, because of decreased immune stimulation, as supported by the ‘hygiene hypothesis’. It has been hypothesized that in genetically susceptible individuals environmental factors operate by triggering an autoimmune response or overloading the β-cells and promoting apoptosis (4). In T1DM, chronic hyperglycemia and, more recently defined, glycemic variability impairs endothelium function through different mechanisms: oxidative stress, polyol pathway activity, free-radical accumulation, non-enzymatic glycosylation of proteins, free-radical accumulation. All these factors are responsible for the development of various degrees of diabetic microangiopathy, like retinopathy, nephropathy, and peripheral neuropathy (6). Thanks to intensive insulin therapy protocols since diagnosis, reproducible long-lasting and rapid-acting human insulin preparations and advances in technological instruments for T1DM management, clinically evident microangiopathy in children and adolescents is almost rarely encountered. However, subclinical signs of vascular impairment can be detected also in adolescence, and are responsible for increased morbidity and mortality in young adulthood, and for impaired quality of life (7, 8). The natural course of T1DM is sometimes complicated by other autoimmune diseases, in particular celiac disease and thyroid disease. Their prevalence and clinical severity are extremely variable, due to different retrospective studies and data collection (9, 10). Customized insulin therapy, continuous self-monitoring of glucose levels, regular physical activity, adequate dietary habits, and screening for diabetes-related complications and co-morbid conditions are the cornerstone for correct management, long-life expectancy, and satisfactory quality of life (11).Vaccines against most recognized infectious diseases are strongly recommended, especially in pediatric patients (12).
1.1 Infections and diabetes mellitus
Even if the role of infections as a trigger of the autoimmune process leading to the clinical onset of T1DM has been extensively studied, few data are available regarding the risk of infections in newly diagnosed and established diabetes. Infectious diseases and T1DM show a bidirectional link: on one hand, poor glycemic control increases the risk of infections, on the other hand, infectious diseases sometimes are the precipitating factor for metabolic decompensation up to diabetic ketoacidosis in both newly-diagnosed and long-lasting patients (13, 14). High blood sugar levels decrease the activity of the immune system and are responsible for changes in tissues, skin, and blood flow, all of which increase the risk of infections (15). If untreated, chronic hyperglycemia impairs leukocyte function and enhances the virulence of several pathogens. In particular, hyperglycemia and/or insulinopenia down-regulate key mediators of host innate humoral and cell-mediated immune response to different pathogens, and reduce the synthesis of pro-inflammatory cytokines (16). As regards cytokines production it has been reported that mononuclear cells and monocytes from T1DM patients secrete less interleukin 1 and interleukin 6. Moreover, chronic hyperglycemia impairs the synthesis of tumor necrosis factor-alpha by T lymphocytes and of IL-10 by myeloid cells (17). Noteworthy, reduced mobilization of polymorphonuclear leukocytes, chemotaxis, and phagocytosis have been observed in the hyperglycemic environment (18). Chronic hyperglycemia impairs host antimicrobial activity by increasing apoptosis and reducing transmigration of polymorphonuclear cells through the endothelium, as well as inhibiting glucose 6 phosphate dehydrogenase (15, 18). Finally, also complement activity is impaired in T1DM patients: lower levels of C4 and subsequent cytokine synthesis and polymorphonuclear dysfunction have been reported (15, 16). Epidemiological studies found that patients with different forms of diabetes mellitus are at increased risk for bacterial complications of pneumococcal infection and for nosocomial bacteriemia, with a mortality rate up to 50% (6). Attention to glycometabolic control reduces morbidity and mortality in T1DM patients, especially within intercurrent illnesses. Strict management of T1DM during intercurrent illnesses is a challenge for pediatric diabetologists (6, 11, 19). If diabetes mellitus itself or degree of metabolic control or underlying immunological dysfunctions influence the susceptibility to infections is debated. Del Roio Liberatore et al. evaluated immunological status in 66 children and adolescents with T1DM and showed only low IgG concentrations and C4B levels related to the degree of glycemic control, without significant impairment of immunological status (20). On the other hand, the impact of infectious diseases on pediatric patients with diabetes mellitus deserves attention. A US retrospective analysis performed on children and adolescents with DM requiring hospitalization for infectious diseases showed a dramatic increase in patients with T1DM (8%), with a longer length of admission (21).
2 Methods
A literature search was carried out in PUBMED, Medline, Embase and in Diabetes Societies websites until May 1st, 2022 for articles published between 2000 and 2022. The search terms used included different combinations of: children, adolescents, diabetes mellitus, infections, diseases, vaccines. The bibliographic search was limited to papers published in English and including case reports, original articles, reviews, consensus and metanalyses. The articles were selected on the basis of the title and abstract.
3 Narrative review
3.1 Respiratory diseases
3.1.1 Tuberculosis
Tuberculosis (TB) is a common comorbidity of diabetes in developing countries and the two diseases share a bidirectional relationship: diabetic people are more prone to contract TB while those with a primary tubercular infection are more likely to have uncompensated diabetes (14). In low and middle-income countries 1.8-45% of inhabitants have TB and 0.1-6% are affected by diabetes mellitus. The risk of TB among people with diabetes mellitus triples that of the healthy population (22) and apparently patient with diabetes mellitus and TB may have an important role in its transmission (23). Notably, patients with T1DM have a higher risk of developing TB when compared to T2DM (24–26).
After primary infection, 90% of individuals with intact immunity control the replication of the bacilli and enter a “latent” phase, asymptomatic, while the remaining 10% develop progressive primary disease. This progression occurs more frequently in patients with poor responses, including unsatisfactory controlled T1DM (as well as HIV infection, chronic kidney failure, or receiving immunosuppressors) (27). Moreover, diabetic patients present an increased risk of TB reactivation, also called post-primary TB, whose symptoms typically begin insidiously along months and affected individuals remain undiagnosed and are potentially infectious for two to three years. These patients can also show more extension cavitation phenomenon (28), or a minimal pleural involvement but more frequently have episodes of haemoptysis (29–31).
TB susceptibility in diabetes mellitus could be explained by the alteration of the function and activation of macrophages, monocytes, and lymphocytes (32, 33); in particular, a reduction in the production of IL-1β in response to Micobacterium tuberculosis has been described (34). IL-1β promotes bacterial containment by inducing specific eicosanoids (35) as well as IL-6 production in a paracrine signalling loop. Importantly, this decrease in cytokine signalling is not specific to Micobacterium tuberculosis, possibly explaining the higher susceptibility to infection showed by diabetic patients (16, 17). At older ages, a role in this susceptibility is probably played also by pulmonary microangiopathy and renal dysfunction (36, 37).
In a systematic review of 13 observational studies, Jeon et al. (22) found that diabetes was positively associated with TB in all but one study, otherwise the risk of developing an active TB varied significantly from 0 to 8 folds, thus confirming the biologically plausible idea that diabetes mellitus increases on average of 3 folds the risk of TB. A recent meta-analysis by Blanco-Guillot demonstrated convincing molecular epidemiological evidence for TB transmission among diabetes mellitus patients but that there is still not enough evidence to draw conclusions about the propensity for patients with both diabetes mellitus and pulmonary TB to cluster according to the genotype of the infecting bacillus (23). In other words, the epidemiological evidence for the relation between diabetes and tuberculosis is strong, but the molecular and immunological basis is yet to be made clear (34).
TB and diabetes mellitus can be a challenging combination to treat because diabetes can inhibit the host immune response to Micobacterium tuberculosis while TB infection as well as some anti-TB drugs, can worsen glycemic control (38), whose efficacy at preventing neuropathy is proven to be more effective T1DM than T2DM (39). Among the issues related to the treatment of TB, the effects of rifampicin on oral antidiabetic agents should be considered; in fact, it could reduce their efficacy and lead to a worse glycemic control (40). Moreover, considering the number of drugs to be used in both conditions, compliance to such a complex polypharmacological treatment needs careful monitoring (41).
Two studies (42) have shown an association between diabetes and multidrug-resistant TB (5-fold more frequent), but contrasting results from other papers (43, 44) make this evidence still inconclusive (45). Intracranial infections (meningitis/encephalitis) caused by TB, as well as Herpes simplex type 2 and group B Streptococcus can lead to diabetic ketoacidosis (46–48).
Bidirectional screening should be indicated: all patients with TB (both latent and active) should be screened for diabetes mellitus and, on the other hand, all individuals with diabetes coming from nations with a high prevalence of TB infection should be tested with a Mantoux test or Quantiferon detection (44, 49).
3.1.2 Pneumococcus and Influenza
No specific research on the influence of pneumococcal infections and influenza and parainfluenza viruses on children with diabetes is available. Anyway, it is well known that individuals affected by diabetes mellitus are far more likely to be hospitalized because of influenza (50) and that Streptococcus pneumoniae represents the first cause of respiratory bacterial infections (15). Therefore, vaccination for these two pathogens is recommended by the American Diabetes Association (51), considering their efficacy in reducing both hospitalization and deaths (52, 53).
3.1.3 COVID-19
The COVID-19 outbreak has recently changed the daily routine of children and adolescents, with a tendency for a sedentary lifestyle and altered dietary habits. Adult patients with T1DM have been included in the high-risk group for COVID-19 infection with high mortality and morbidity rate and priority was given once vaccination was available (54). As regards children with T1DM, in the first year of pandemics evidence was weak. A recent study by Woodruff et al. (55) calculated age-adjusted cumulative population-based rates of severe COVID-19 among 2293 children primarily hospitalized for COVID-19 in the period March 2020 to May 2021 (before vaccination): notably, in the age group 2-17 years diabetes mellitus (both type 1 and 2) affected 88 patients and was associated with increased risk of more severe course (aRR: 1.9; 95% CI: 1.6-2.3).
More T1DM diagnoses in children (56, 57) and increased frequency and severity of Diabetic KetoAcidosis (DKA) at the time of diabetes diagnosis (58) have been reported in European pediatric populations during the pandemic. Using IQVIA health care data from March 2020 to February 2021, the CDC estimated diabetes incidence among patients aged <18 years with diagnosed COVID-19 demonstrating a significantly higher incidence when compared with children without COVID-19 (hazard ratio = 2.66, 95% CI = 1.98-3.56) (59).
In Germany from January 2020 to June 2021, 5,162 children and adolescents with new-onset T1DM were registered, with an observed incidence significantly higher than the expected one (60) and monthly peaks happening about 3 months after each COVID-19 peak. The increased risk for diabetes among children who had COVID-19 highlights the importance of vaccination as an active prevention strategy (19).
3.2 Urinary tract infections
Urinary tract infections (UTI) are frequently reported in diabetic patients, mainly related to inadequate glycemic control, diabetic microangiopathy, anatomic abnormalities of the urinary tract and, in girls, recurrent vaginitis (61).The spectrum of UTIs in adults ranges from asymptomatic bacteriuria (ASB) to cystitis and pyelonephritis (sometimes of emphysematous type) to severe urosepsis. The diagnosis of UTI should be suspected if dysuria, urgent urination, sovrapubic pain, or fever with chills occur (62).
Data concerning UTI and ASB in diabetic patients mainly regard adults (63–65) and the possible effect on causing pyelonephritis is unclear. Barnabas et al. found that the prevalence of ASB was higher in 178 children and young adults with T1DM (10.1%) than in matched control subjects (2.6%) and that the spectrum of bacteria in ASB (Streptococcus agalactiae, Enterococcus spp., Escherichia coli, Klebsiella pneumoniae) was different from the one typically related to UTI (mainly Escherichia coli) (66, 67). As for diabetic women (68), the recommendation of antibiotic therapy in case of ASB in diabetic children remains controversial (69, 70).
Candida spp. represents the vast majority of fungal colonization of the urinary tract of diabetic people, causing infection when symptoms or pyuria occur (71).
Emphysematous cystitis (ECy) and pyelonephritis (EP), are characterized by the presence of gas in the bladder wall and in the perinephric tissues or collecting system, respectively. They are more observed in adult women, mainly caused by Escherichia coli (72). A single pediatric case of ECy pertains to a young girl aged 15 years admitted to the emergency department for abdominal and back pain and with a history of recurrent urinary tract infections and grade 1 left-sided vesicoureteral reflux: the swab for SARS-CoV-2 resulted positive and an HbA1c of 76 mmol/mol (9.1%) and blood glucose of 200 mg/dL were recorded, consistent with new-onset diabetes mellitus (73).
3.3 Gastrointestinal infections
Few data are available regarding surgical illnesses in pediatric patients with chronic diseases. Diagnosis of acute appendicitis in pediatric patients with diabetes mellitus is sometimes difficult, and prompt clinical recognition is a challenge to prevent complications related to a delayed diagnosis. In fact, clinical signs and symptoms (i.e., abdominal pain, vomiting) can be attributed to diabetic ketoacidosis and vice-versa (74). Similarly, delayed gastric emptying due to autonomic neuropathy, even if extremely rare in pediatric patients, could be responsible for abdominal pain (75, 76).
Three reports describe acute appendicitis in pediatric diabetes. In 1988 Latchav reported acute appendicitis in children with diabetes (77). A more recent retrospective examination of the medical records of children with previously diagnosed diabetes mellitus and admitted for acute appendicitis reported clinical characteristics in 18 children, 17 with T1DM. The authors reported a similar presentation as compared to controls, and only fever was less frequent. Perforation was observed in 33% of cases Noteworthy, patients with diabetes showed postoperative severe hyperglycemic crises, suggesting that strict glycometabolic control is mandatory, especially after surgery. No wound complications were reported (78). Finally, a rare case of non-typhoid Salmonella infection in a diabetic girl with atypical presentation of acute appendicitis was described (79).
Acalculous cholecystitis has been reported in adults affected by diabetes mellitus, while it is extremely rare in the pediatric age group (80). Emphysematous cholecystitis (EC), which represents less than 1% of cholecystitis, is caused by gas-forming bacteria, (i.e. Clostridium welchii, Escherichia Coli, Staphylococcus, and anaerobic Streptococci) and its clinical presentation varies from mild abdominal pain to septic shock. EC has been diagnosed in an adolescent with fever, abdominal pain, and vomiting (81). Clinical, laboratory and radiological examinations revealed the amount of gas in the gallbladder wall or in the surrounding tissues were compatible with EC, complicated by pericholecystic fluid collection and secondary acute appendicitis. Gallbladder atony with biliary stasis and small-vessel vasculitis have been considered predisposing factors (82).
Similarly, pyogenic liver abscess (PLA) has been reported in adults, and about 50% of cases affected by diabetes. A fever of unknown origin was diagnosed, and abdominal ultrasound showed a fluid-filled mass in the right hepatic lobe. Percutaneous drainage of the mass revealed an occult pyogenic liver abscess caused by Klebsiella pneumoniae, and intravenous antibiotic treatment was followed by recovery. As reported in other cases, unsatisfactory glycemic control is the most important risk factor (83).
The prevalence of fungal infections in human beings has recently increased. Candida albicans is the most frequently isolated and proliferates as an opportunistic pathogen as part of intestinal microbiota. Pediatric patients with T1DM showed higher species diversity of the yeast-like fungi, with reduced prevalence of Candida albicans as compared to controls, otherwise increased resistance to common antifungal treatment (84). On the other hand, patients with diabetes mellitus are more susceptible to intestinal candidiasis, due to a hyperglycemic environment and to immunological dysfunction. Risk factors are poor glycemic control, prolonged steroids, antibiotics and antifungals use, female gender. Even if vaginal candidiasis has been extensively described in patients with T1DM, few and conflicting data are available on the prevalence of gastrointestinal candidiasis and antifungal susceptibility (85). Kowalewska reported a prevalence of gastrointestinal candidiasis of 75.5% in children and adolescents with T1DM (86), while others found a prevalence ranging from 2.5% to 9.7% (87). On the other hand, oral candidiasis and gingivitis were observed in a cohort of pediatric patients with T1DM and high levels of HbA1c (88). In a cohort of adolescents with T1DM, despite multiple subcutaneous daily injections, serological evidence of hepatitis A, B, C, and E was similar to controls (89).
Helicobacter pylori (HP) is a gram-negative bacterium whose frequency has been increasing worldwide, especially among people with low socioeconomic conditions. HP infection affects mainly stomach and several organs of the gastrointestinal tract, otherwise extra gastric manifestations have been described (90). HP has been observed in patients with different age, even in childhood, and if not treated persists over time and is a risk factor for severe complications, including gastritis, gastric and duodenal low-grade lymphomas, hepatic and gastric carcinoma. Moreover, HP infection has been linked to insulin resistance and vascular complications (91). Children with T1DM have been considered at high risk of HP infection and its consequences, even if metabolic control is satisfactory (92). A case-control study in children and adolescents with T1DM reported a higher frequency of HP infection (60%) as compared to controls (40%), positively related to disease duration. Age, insulin requirement, degree of metabolic control, gastrointestinal symptoms frequency were similar between positive or negative patients (93). A longitudinal study aimed to evaluate the reinfection rate of HP in pediatric patients with T1DM showed a higher frequency of HP infection (24%) and reinfection rate (33%) as compared to controls (7% and 4.5%, respectively). Reinfection rate was associated with socioeconomic status and chronological age (94).The eradication of HP in pediatric patients did not improve degree of metabolic control of diabetes (95).
Ascaris lumbricoides and Giardia lamblia were not frequently reported in a cohort of T1DM patients, nevertheless Ascaris lumbricoides has been described as a complicating factor in an adolescent with recurrent DKA (96).
3.4 Dermatological infections
It has been reported that up to 30% of patients with diabetes will develop skin abnormalities throughout their lives, frequently related to the time they elapsed from the clinical onset of the disease (97). Among cutaneous complications, infections occur in all age groups, sometimes detectable at the time of clinical diagnosis of both forms of diabetes mellitus.
In children and adolescents with diabetes mellitus severe, recurrent atypical cutaneous infections are frequently described, associated with poor metabolic control and obesity (98, 99). Recently, the widespread use of technological devices for self-monitoring of glucose levels and pumps for insulin administration increased the risk of local dermatological complications (100).
In patients with diabetes, the skin infections more frequently described are fungal and bacterial, while no specific viral strains are involved. On the other hand, an anecdotic report described multiple herpetic whitlows in a child performing self-monitoring of blood glucose (101). Direct contact between damaged skin and secretion containing the virus (i.e. labial herpes) has been considered a causative factor. Pediatric patients with diabetes have a high susceptibility to infections caused by dermatophytes Candida spp, including tinea pedis, onychomycosis caused by Trichophyton rubrum and Trichophyton mentagrophytes (102). Candidiasis of flexures and mucous membranes have been described, in particular vulvovaginitis, balanitis, and angular cheilitis, being reported in up to 5% of patients (103). A prospective study in 32 female children and adolescents with T1DM showed Candida spp in 52.5% of cases, with higher frequency as compared to controls (18.2%). C. albicans was the predominant species (72.7%), followed by Candida glabrata (22.7%), Candida tropicalis (2.3%), and Candida parapsilosis (2.3%) (104). It is noteworthy that Candida glabrata strains are more resistant to fluconazole treatment (105).
As regards bacterial skin infections, Staphylococcus aureus has been reported frequently in T1DM, being responsible for infections ranging from skin and soft tissue localization up to more invasive manifestations such as osteomyelitis, septic arthritis, pneumonia, and bacteriemia (106). The role of methicillin-resistant Staphylococcus aureus has been studied in adult diabetic foot ulcers, while reports on Staphylococcus aureus infection in young patients without foot damage are lacking. Noteworthy, an educational intervention aimed to prevent foot infections in young patients is essential (107). For this purpose, Menne et al. prospectively evaluated all pediatric patients with diabetes mellitus and Staphylococcus aureus infection between 2002 and 2010. They identified 47 cases, 43 with skin and soft tissue infections and 4 with osteomyelitis. Female gender, poor metabolic control, obesity, methicillin-resistant strain, and recurrent infections have been reported in the majority of cases (106). Other infections due to Staphylococcus aureus are folliculitis and impetigo, while boils and anthrax are rarely encountered (98).
Patients with obesity and diabetes mellitus are affected by intertrigo, characterized by redness in the body folds with secretion and odor, requiring local hygiene, topical antibiotics and in some cases low potency corticosteroids. If not correctly treated, intertrigo can be followed by superinfection with Candida albicans, whose treatment includes topical antifungals (98). Other infections are pachyonychia, furunculosis, and anthrax, caused by Staphylococci, and erythrasma caused by Corynebacterium minutissimi.
The widespread use of technological devices for T1DM management increased the frequency of cutaneous complications. A web-based survey regarding dermatological complications related to pumps or glucose sensors was administered to 139 patients with T1DM from 2 pediatric Italian Centers (108). Skin reaction have been reported in 51.1% of patients, in particular allergic contact dermatitis consisting of vesicles, erythema, edema, and pruritus. It has been hypothesized that repeated taping of the same sites and trauma of repeated insertions are the most important causative factors, together with harmful agents in the devices, like isobornyl acrylate, NN-dimethylacrilamide, and colophonium (108).
The careful examination of the injection sites is mandatory since bacterial colonization of the sensor electrodes has been recently reported (109). The microbiological test performed on sensor electrodes from 31 children with T1DM showed bacterial colonization in 39% of cases. The most frequently encountered strain was methicillin-sensitive coagulase-negative Staphylococcus, otherwise methicillin-resistant coagulase-negative Staphylococcus aureus, Klebsiella pneumoniae, Bacillus sonorensis, Ochrobactrum tritici have been isolated.
3.5 Soft tissues infections
Necrotizing fasciitis (NF) is a severe infection of soft tissues that usually involves the limbs and tacks along fascial planes (110, 111). It has been described in adults with diabetes mellitus as a risk factor for mortality. It is rare in the pediatric age group, and Varicella-Zoster virus or Group A, β-hemolytic streptococcal infections seem to be predisposing factors. Conwell et al. described 2 adolescents with poorly controlled T1DM who developed polymicrobial NF after different degrees of trauma involving the perineal region (112). Candida superinfection and surgical debridement have been reported in one case, and septic shock and suspected osteomyelitis in another. Both patients required prolonged intravenous antibiotic treatment and correction of hypocalcemia complicating the infection. The paucity of cutaneous signs in the early stage of the disease together with intense pain even in absence of tissue damage, otherwise with a history of even mild trauma, should induce suspicion of NF (112).
Another soft tissue complication is iliopsoas abscess (IA). IA is a life-threatening form of extraperitoneal infection involving the psoas and iliac muscles. The classic clinical triad consists of fever, flank pain, and limitation of hip movements (113). Hematological or contiguous anatomical structure spread or local trauma with subsequent hematoma are the causative factors, and Staphylococcus aureus is the most frequent microbiological organism isolated in adults. Up to the recent past, IA complicated spine tuberculosis, while more recently predisposing factors are immunological defects, drug abuse, alcoholism, and diabetes mellitus. IA has been observed in adults with diabetes mellitus, while to our knowledge, only 2 case reports described IA in pediatric diabetes. In the majority of cases spinal epidural abscesses were diagnosed (114). Another more recent report described IA in three adolescents with T1DM, poorly controlled in 2/3 cases. All patients showed fever, flank, and/or back pain, requiring prolonged antibiotic treatment; the abscess was diagnosed by Computer Tomography (CT) scan (115).
3.6 Rhinocerebral zygomycosis
Zygomycosis is a rare life-threatening opportunistic fungal infection in humans, that can complicate both diabetes mellitus and immunodeficiency syndromes characterized by defects of the cell-mediated immunity (116). In particular, RhinOCerebral Mucormycosis (ROCM) is the most frequent form of mucormycosis in patients with diabetes mellitus (117). The responsible organism is an aerobic saprophytic fungus belonging to the order of Mucorales, class of Zygomycetes (118). The fungal infection is caused either by inhalation of sporangiospores or via direct contamination of skin wounds, and mainly involves the lungs, nasal cavity and paranasal sinuses, gut, and skin (119). Among the mechanisms involved in the higher incidence of mucormycosis in diabetic patients, there are the greater availability of glucose, a lower response of T-cells, and the increased expression of host receptors mediating the invasion of epithelial cells (119). Indeed, in the case of ketoacidosis, the fungal growth is favored by the low pH, due to hyperglycemia as well as higher levels of free iron ions (116). Furthermore, hyperglycemia and the associated metabolic acidosis, are responsible for impaired neutrophil function, neuropathies, and vascular insufficiency, which lead to a diminished resistance to infections and altered tissue response (116).
The prerequisites for the diagnosis of zygomycosis are a high index of suspicion, recognition of host factors, and prompt assessment of clinical manifestations (120). Corzo-Leon et al. proposed an algorithm for the diagnosis of ROMC in diabetic patients: “red flags” include cranial nerve palsy, diplopia, sinus pain, blepharoptosis, proptosis, acute ocular motility changes, internal or external ophthalmoplegia, headache, acute vision loss, periorbital swelling, orbital apex syndrome, and ulcers of the palate (117, 121). Microscopy (both direct and tissue histopathology) and cultures of different specimens represent the gold standard to diagnose zygomycosis. Tissue histopathology shows inflammation in the majority of cases, neutrophilic or granulomatous, sometimes lacking in immunosuppressed patients (120). Imaging (e.g., preoperative contrast-enhanced CT) is a fundamental guide for initial diagnosis, as well as a tool to delimit the infected zone and plan surgical boundaries (121). CT scan will show edematous mucosa, fluid-filled ethmoid sinuses, and destruction of periorbital tissues and bone margins. Notably, bone destruction is generally a late effect occurring after soft-tissues necrosis. Magnetic resonance images (MRI) can also have a role in identifying the intradural and intracranial extent, a cavernous sinus thrombosis, or thrombosis of the cavernous portions of the internal carotid artery. Contrast-enhanced MRI can demonstrate the perineural spread of the infection (117).
The mainstay of mucormycosis treatment is the combination of intravenous antifungal therapy, surgery, and active management of the underlying condition (e.g., decompensated diabetes mellitus). Intravenous liposomal amphotericin B successfully penetrates the central nervous system, thus being used for invasive mucormycosis (122). Posaconazole is a new triazole with a broad antifungal spectrum and its administration seems to be associated with a higher survival rate (116). Di Coste et al. described a case of ROMC pansinusitis in a 14-year-old girl with T1DM; the patient had a 7-day-long history of dental pain, associated with facial swelling, palpebral ecchymosis, and left eye decreased visual acuity, unresponsive to first-line antibiotic therapy. Head MRI showed marked mucosal thickening of the left maxillary sinus extended to the sphenoid, ethmoid, and frontal sinus. Inflammatory tissue was excided through an endoscopic sinus surgery and cultures revealed growth of Zygomycetes. Due to the severe impairment and extended infection, intravenous amphotericin B was started but shortly switched to posaconazole because of severe side effects (hyperglycemia, marked hypothermia, and profuse sweating). A very slow improvement was observed, with poor glycemic control. Unfortunately, the patient ultimately developed blindness in her left eye (116). In conclusion, given the rapid course of ROCM and the high mortality risk if the microorganism overcomes the skull, every pediatric patient with T1DM and signs or symptoms belonging to the abovementioned “red flags” should be a candidate for prompt imaging evaluation and nasal endoscopy, in order to rule out mucormycosis and start antifungal therapy.
3.7 Oral infections
Infections of the oral cavity represent a heterogeneous group of infectious diseases that can be caused by a wide range of microorganisms. Children with T1DM are at higher risk of developing oral infections than the healthy pediatric population, this being a consequence of reduced salivary flow, modified salivary composition (particularly in decompensated diabetes), and a change in the oral bacterial flora (88, 123). A larger secretion of inflammatory mediators, the impaired immune cell function, the glycation of proteins, and the altered wound healing are all factors potentially contributing to more frequent and sometimes also more severe oral infections in T1DM (123). In detail, the impaired immune cell function consists of defective chemotaxis and reduced phagocytosis; diabetic patients with severe infection have depressed PMN chemotaxis compared to those with mild infection or non-diabetic subjects with severe or mild infection (123). Moreover, the synthesis, maturation, and homeostasis of collagen seem to be affected by glucose levels, undergoing nonenzymatic glycation which results in the irreversible formation of altered proteins known as Advanced Glycation End-products (AGEs). Notably, high levels of AGEs determine enhanced oxidative stress at the level of gingival tissues. TNF-α also has a crucial role in case of infections in patients with TIDM, stimulating fibroblasts to synthesize matrix-degrading enzymes and suppressing insulin peripheral effect by both phosphorylations of a serine residue of the Insulin Receptor Substrate 1 (IRS-I) and reduction of the mRNA expression of IRS-I and GLUT-4 (124–126).
Ueta et al. demonstrated that diabetes mellitus is a predisposing condition for odontogenic infections and oral candidiasis; moreover, diabetes-complicated infections are more severe, with higher C-reactive protein and erythrocyte sedimentation rate levels (127). Gomez-Diaz et al. evaluated the association between carotid Intima-Media Thickness (cIMT), buccodental status, and glycemic control in children with T1DM and found that those with HbA1c > 69 mmol/mol (8.5%) had greater frequency of caries, gingivitis, and enamel demineralization, and were positive for Streptococcus mutans and Candida albicans; moreover, in these patients cIMT increased and vessel compliance decreased compared to those with HbA1c <53 mmol/mol (7.0%; p < 0.05) (128). Safia et al. compared salivary samples from diabetic patients with healthy controls and showed that diabetics had a higher candidal carriage rate compared to controls; in particular, Candida albicans was the most frequently isolated species, but diabetics patients had a much wider variety of species compared with controls (129).
Candida albicans is among the most frequent causes of oral cavity infections in children with T1DM, being responsible for various clinical forms including maxillofacial involvement, pseudomembranous form (classic onset, with xerostomia), rhomboid glossitis, perioral dermatitis, and angular cheilitis (125). Arslan et al. showed significant differences in terms of isolated Candida frequency between healthy subjects and diabetic patients, but no difference between the groups in terms of virulence (130). Cytologic preparation is essential for diagnosis, being the morphologic forms of Candida spp the most significant finding (with the bacterial load which normally colonizes the mouth being an interesting, but minor element). The azole class of antifungal medications (e.g., itraconazole, clotrimazole, fluconazole) exerts its action by preferentially inhibiting fungal cytochrome P450, an essential element to continue ergosterol production and let the microorganisms grow (129).
Olczak-Kowalczyk et al. compared a group of children with T1DM and no other chronic disease and a group of healthy children for oral fungal infection and its course. Candida spp often occurred in healthy patients, but oral candidiasis was found only in the diabetes groups (11.4%). Gingivitis occurred more frequently in patients with diabetes and its severity was correlated with higher glycemia and glycated haemoglobin > 64 mmol/mol (8%) (88). In conclusion, oral cavity infections and T1DM are bi-directionally associated: the inadequate control of glucose levels may potentiate the severity of plaque-related gingivitis.
4 Conclusions
We evaluated the different infectious diseases associated with pediatric diabetes mellitus. It is noteworthy that, despite the improved management of the disease, infections still represent a severe risk factor, especially in cases of unsatisfactory control. An unusual initial clinical presentation or symptoms attributed to diabetes itself can delay diagnosis and a more severe course of infection can negatively affect the outcome. Good metabolic control and careful clinical evaluation are the cornerstones to prevent infections, together with adherence to the recommended vaccination program. Pediatric diabetologists should be aware of the risk connected with infectious diseases, and patients should be adequately taught about the “sick day management” to prevent DKA.
Author contributions
Conceptualization: GPi and Gd’A. Methodology: GPi, NM, FN, GPa, and Gd’A. Writing—original draft preparation: GPi, ER, MB, and Gd’A. Writing—review and editing: GPi and Gd’A. Supervision: GPa, MM, and Gd’A. All authors have read and agreed to the published version of the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet (2018) 391:2449–62. doi: 10.1016/S0140-6736(18)31320-5
2. Lawrence JM, Divers J, Isom S, Saydah S, Imperatore G, Pihoker C, et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA (2021) 326:717–27. doi: 10.1001/JAMA.2021.11165
3. Xia Y, Xie Z, Huang G, Zhou Z. Incidence and trend of type 1 diabetes and the underlying environmental determinants. Diabetes Metab Res Rev (2019) 35:e3075. doi: 10.1002/DMRR.3075
4. Giwa AM, Ahmed R, Omidian Z, Majety N, Karakus KE, Omer SM, et al. Current understandings of the pathogenesis of type 1 diabetes: Genetics to environment. World J Diabetes (2020) 11:13–25. doi: 10.4239/wjd.v11.i1.13
5. Dedrick S, Sundaresh B, Huang Q, Brady C, Yoo T, Cronin C, et al. The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis. Front Endocrinol (Lausanne) (2020) 11:78/BIBTEX. doi: 10.3389/FENDO.2020.00078/BIBTEX
6. Donaghue KC, Marcovecchio ML, Wadwa RP, Chew EY, Wong TY, Calliari LE, et al. ISPAD clinical practice consensus guidelines 2018: Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes (2018) 19:262–74. doi: 10.1111/PEDI.12742
7. Giannopoulou EZ, Doundoulakis I, Antza C, Christoforidis A, Haidich AB, Kotsis V, et al. Subclinical arterial damage in children and adolescents with type 1 diabetes: A systematic review and meta-analysis. Pediatr Diabetes (2019) 20:668–77. doi: 10.1111/PEDI.12874
8. Carlsen S, Skrivarhaug T, Thue G, Cooper JG, Gøransson L, Løvaas K, et al. Glycemic control and complications in patients with type 1 diabetes – a registry-based longitudinal study of adolescents and young adults. Pediatr Diabetes (2017) 18:188–95. doi: 10.1111/PEDI.12372
9. Parkkola A, Härkönen T, Ryhänen SJ, Uibo R, Ilonen J, Knip M. Transglutaminase antibodies and celiac disease in children with type 1 diabetes and in their family members. Pediatr Diabetes (2018) 19:305–13. doi: 10.1111/PEDI.12563
10. Jonsdottir B, Larsson C, Carlsson A, Forsander G, Ivarsson SA, Lernmark A, et al. Thyroid and islet autoantibodies predict autoimmune thyroid disease at type 1 diabetes diagnosis. J Clin Endocrinol Metab (2017) 102:1277–85. doi: 10.1210/JC.2016-2335
11. Danne T, Phillip M, Buckingham BA, Jarosz-Chobot P, Saboo B, Urakami T, et al. ISPAD clinical practice consensus guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes (2018) 19:115–35. doi: 10.1111/PEDI.12718
12. Morgan E, Halliday SR, Campbell GR, Cardwell CR, Patterson CC. Vaccinations and childhood type 1 diabetes mellitus: A meta-analysis of observational studies. Diabetologia (2016) 59:237–43. doi: 10.1007/S00125-015-3800-8/TABLES/2
13. Burekovic A, Dizdarevic-Bostandzic A, Godinjak A. Poorly regulated blood glucose in diabetic patients–predictor of acute infections. Med Arch (2014) 68:163. doi: 10.5455/MEDARH.2014.68.163-166
14. Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a Large primary care cohort study. Diabetes Care (2018) 41:2127–35. doi: 10.2337/DC18-0287
15. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab (2012) 16 Suppl 1:27. doi: 10.4103/2230-8210.94253
16. Muller LMAJ, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AIM, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis (2005) 41:281–8. doi: 10.1086/431587/2/41-3-281-TBL004.GIF
17. Geerlings SE, Brouwer EC, Van Kessel KCPM, Gaastra W, Stolk RP, Hoepelman AIM. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest (2000) 30:995–1001. doi: 10.1046/J.1365-2362.2000.00745.X
18. Peleg AY, Weerarathna T, McCarthy JS, Davis TME. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev (2007) 23:3–13. doi: 10.1002/DMRR.682
19. d’Annunzio G, Maffeis C, Cherubini V, Rabbone I, Scaramuzza A, Schiaffini R, et al. Caring for children and adolescents with type 1 diabetes mellitus: Italian society for pediatric endocrinology and diabetology (ISPED) statements during COVID-19 pandemia. Diabetes Res Clin Pract (2020) 168:1–11. doi: 10.1016/J.DIABRES.2020.108372
20. Del Roio Liberatore R, Barbosa SFC, Alkimin M das G, Bellinati-Pires R, Florido MPC, Isaac L, et al. Is immunity in diabetic patients influencing the susceptibility to infections? immunoglobulins, complement and phagocytic function in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes (2005) 6:206–12. doi: 10.1111/J.1399-543X.2005.00136.X
21. Korbel L, Easterling RS, Punja N, Spencer JD. The burden of common infections in children and adolescents with diabetes mellitus: A pediatric health information system study. Pediatr Diabetes (2018) 19:512–9. doi: 10.1111/PEDI.12594
22. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PloS Med (2008) 5:e152. doi: 10.1371/journal.pmed.0050152
23. Blanco-Guillot F, Delgado-Sánchez G, Mongua-Rodríguez N, Cruz-Hervert P, Ferreyra-Reyes L, Ferreira-Guerrero E, et al. Molecular clustering of patients with diabetes and pulmonary tuberculosis: A systematic review and meta-analysis. PloS One (2017) 12:e0184675. doi: 10.1371/JOURNAL.PONE.0184675
24. Shen TC, Lin CL, Wei CC, Liao WC, Chen WC, Chen CH, et al. Increased risk of tuberculosis in patients with type 1 diabetes mellitus: Results from a population-based cohort study in Taiwan. Med (United States) (2014) 93:e96. doi: 10.1097/MD.0000000000000096
25. Swai ABM, Mclarty DG, Mugusi F. Tuberculosis in diabetic patients in tanzania. Trop Doct (1990) 20:147–50. doi: 10.1177/004947559002000402
26. Dobler CC, Flack JR, Marks GB. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open (2012) 2:e000666. doi: 10.1136/BMJOPEN-2011-000666
27. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet (2010) 375:1814–29. doi: 10.1016/s0140-6736(10)60483-7
28. Shewade HD, Jeyashree K, Mahajan P, Shah AN, Kirubakaran R, Rao R, et al. Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-diabetes: A systematic review. PloS One (2017) 12:e0186697. doi: 10.1371/JOURNAL.PONE.0186697
29. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med (2011) 9:1–15. doi: 10.1186/1741-7015-9-81
30. Viswanathan V, Vigneswari A, Selvan K, Satyavani K, Rajeswari R, Kapur A. Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis–a report from south India. J Diabetes Complications (2014) 28:162–5. doi: 10.1016/J.JDIACOMP.2013.12.003
31. Kornfeld H, Sahukar SB, Procter-Gray E, Kumar NP, West K, Kane K, et al. Impact of diabetes and low body mass index on tuberculosis treatment outcomes. Clin Infect Dis (2020) 71:e392–8. doi: 10.1093/CID/CIAA054
32. Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJAM, Van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Heal (2010) 15:1289–99. doi: 10.1111/j.1365-3156.2010.02625.x
33. Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract (2014) 106:191–9. doi: 10.1016/J.DIABRES.2014.06.011
34. Lachmandas E, Thiem K, van den Heuvel C, Hijmans A, de Galan BE, Tack CJ, et al. Patients with type 1 diabetes mellitus have impaired IL-1β production in response to mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis (2018) 37:371–80. doi: 10.1007/S10096-017-3145-Y/FIGURES/6
35. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nat 2014 5117507 (2014) 511:99–103. doi: 10.1038/nature13489
36. Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis (2013) 93:S10–4. doi: 10.1016/S1472-9792(13)70004-0
37. Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol (2014) 44:617–26. doi: 10.1002/EJI.201344301
38. Niazi AK, Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control. J Diabetes Metab Disord 2012 111 (2012) 11:1–4. doi: 10.1186/2251-6581-11-28
39. Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. BMJ (2014) 348:1–9. doi: 10.1136/BMJ.G1799
40. McMurry HS, Mendenhall E, Rajendrakumar A, Nambiar L, Satyanarayana S, Shivashankar R. Coprevalence of type 2 diabetes mellitus and tuberculosis in low-income and middle-income countries: A systematic review. Diabetes Metab Res Rev (2019) 35:e3066. doi: 10.1002/DMRR.3066
41. Unnikrishnan R, Misra A. Infections and diabetes: Risks and mitigation with reference to India. Diabetes Metab Syndr Clin Res Rev (2020) 14:1889–94. doi: 10.1016/J.DSX.2020.09.022
42. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the bellevue chest service, 1987 to 1997. Chest (2001) 120:1514–9. doi: 10.1378/CHEST.120.5.1514
43. Suárez-García I, Rodríguez-Blanco A, Vidal-Pérez JL, García-Viejo MA, Jaras-Hernández MJ, López O, et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 2008 284 (2008) 28:325–30. doi: 10.1007/S10096-008-0627-Y
44. Chiang CY, Bai KJ, Lin HH, Chien ST, Lee JJ, Enarson DA, et al. The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis. PloS One (2015) 10:e0121698. doi: 10.1371/JOURNAL.PONE.0121698
45. Bailey SL, Grant P. ‘The tubercular diabetic’: the impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. Clin Med (Northfield Il) (2011) 11:344–7. doi: 10.7861/CLINMEDICINE.11-4-344
46. Elmas ÖN, Akinci A, Bilir P. Tuberculous meningitis associated with diabetic ketoacidosis. J Clin Res Pediatr Endocrinol (2011) 3:222. doi: 10.4274/JCRPE.373
47. Aydin Y, Ustun I, Erol K, Ozkaya E, Gul K, Berker D, et al. Herpes simplex type-2 encephalitis masked by diabetic ketoacidosis. J Natl Med Assoc (2005) 97:722.
48. Raichur DV, Deshpande RV, Chandragowda DK. Tuberculous meningitis associated with diabetic ketoacidosis. Indian Pediatr (1999) 36:1183–4.
49. Bloomgarden Z, Misra A. Diabetes and tuberculosis: An important relationship. J Diabetes (2017) 9:640–3. doi: 10.1111/1753-0407.12547
50. Miller AC, Subramanian RA, Safi F, Sinert R, Zehtabchi S, Elamin EM. Influenza a 2009 (H1N1) virus in admitted and critically ill patients. J Intensive Care Med (2012) 27:25–31. doi: 10.1177/0885066610393626
51. ADA’s standards of medical care in diabetes. Clin Diabetes (2021) 39:128. doi: 10.2337/cd21-pe01
52. Kondrashova A, Nurminen N, Patrikainen M, Huhtala H, Lehtonen J, Toppari J, et al. Influenza a virus antibodies show no association with pancreatic islet autoantibodies in children genetically predisposed to type 1 diabetes. Diabetologia (2015) 58:2592–5. doi: 10.1007/S00125-015-3723-4/TABLES/1
53. Demirci I, Haymana C, Salman S, Tasci I, Corapcioglu D, Kirik A, et al. Rates and associates of influenza and pneumococcus vaccination in diabetes mellitus: A nationwide cross-sectional study (TEMD vaccination study). World J Diabetes (2021) 12:2107–18. doi: 10.4239/WJD.V12.I12.2107
54. Kastora S, Patel M, Carter B, Delibegovic M, Myint PK. Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta-analysis. Endocrinol Diabetes Metab (2022) 5:e00338. doi: 10.1002/EDM2.338
55. Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. Pediatrics (2022) 149:2021053418. doi: 10.1542/PEDS.2021-053418/183463
56. Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-onset type 1 diabetes in children during COVID-19: Multicenter regional findings in the U.K. Diabetes Care (2020) 43:e170–1. doi: 10.2337/DC20-1551
57. Vlad A, Serban V, Timar R, Sima A, Botea V, Albai O, et al. Increased incidence of type 1 diabetes during the COVID-19 pandemic in Romanian children. Med (2021) 57:973. doi: 10.3390/MEDICINA57090973
58. Kamrath C, Mönkemöller K, Biester T, Rohrer TR, Warncke K, Hammersen J, et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA (2020) 324:801–4. doi: 10.1001/JAMA.2020.13445
59. Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, et al. Risk for newly diagnosed diabetes 30 days after SARS-CoV-2 infection among persons aged 18 years — united states, march 1, 2020–June 28, 2021. MMWR Morb Mortal Wkly Rep (2022) 71:59–65. doi: 10.15585/MMWR.MM7102E2
60. Kamrath C, Rosenbauer J, Eckert AJ, Siedler K, Bartelt H, Klose D, et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: Results from the DPV registry. Diabetes Care (2022) 45:1762–71. doi: 10.2337/DC21-0969
61. Julka S. Genitourinary infection in diabetes. Indian J Endocrinol Metab (2013) 17:S83. doi: 10.4103/2230-8210.119512
62. Kofteridis DP, Papadimitraki E, Mantadakis E, Maraki S, Papadakis JA, Tzifa G, et al. Effect of diabetes mellitus on the clinical and microbiological features of hospitalized elderly patients with acute pyelonephritis. J Am Geriatr Soc (2009) 57:2125–8. doi: 10.1111/J.1532-5415.2009.02550.X
63. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care (2003) 26:510–3. doi: 10.2337/DIACARE.26.2.510
64. Chen SL, Jackson SL, Boyko EJ. Diabetes mellitus and urinary tract infection: Epidemiology, pathogenesis and proposed studies in animal models. J Urol (2009) 182:S51–6. doi: 10.1016/J.JURO.2009.07.090
65. Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care (2011) 34:230–5. doi: 10.2337/DC10-0421
66. Rózsai B, Lányi E, Soltész G. Asymptomatic bacteriuria and leukocyturia in type 1 diabetic children and young adults. Diabetes Care (2003) 26:2209–10. doi: 10.2337/DIACARE.26.7.2209-A
67. Shaikh N, Wald ER, Keren R, Gotman N, Ivanova A, Carpenter MA, et al. Predictors of non- escherichia coli urinary tract infection. Pediatr Infect Dis J (2016) 35:1266–8. doi: 10.1097/INF.0000000000001301
68. Geerlings SE. Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents (2008) 31:54–7. doi: 10.1016/J.IJANTIMICAG.2007.07.042
69. Stein G, Funfstuck R. Asymptomatic bacteriuria–what to do. Nephrol Dial Transplant (1999) 14:1618–21. doi: 10.1093/NDT/14.7.1618
70. Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the infectious diseases society of America. Clin Infect Dis (2019) 68:e83–e110. doi: 10.1093/CID/CIY1121
71. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med (2002) 113:80–4. doi: 10.1016/S0002-9343(02)01062-8
72. Schainuck LI, Fouty R, Cutler RE. Emphysematous pyelonephritis. A New Case Rev previous observations. Am J Med (1968) 44:134–9. doi: 10.1016/0002-9343(68)90245-3
73. Cao BL, Brewer O, Cross AR. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. BMJ Case Rep CP (2022) 15:e245779. doi: 10.1136/BCR-2021-245779
74. Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care (2002) 17:63–7. doi: 10.1053/JCRC.2002.33030
75. Höliner I, Haslinger V, Lütschg J, Müller G, Barbarini DS, Fussenegger J, et al. Validity of the neurological examination in diagnosing diabetic peripheral neuropathy. Pediatr Neurol (2013) 49:171–7. doi: 10.1016/J.PEDIATRNEUROL.2013.03.014
76. Rasmussen VF, Jensen TS, Tankisi H, Karlsson P, Vestergaard ET, Kristensen K, et al. Large Fibre, small fibre and autonomic neuropathy in adolescents with type 1 diabetes: A systematic review. J Diabetes Complications (2021) 35:108027. doi: 10.1016/J.JDIACOMP.2021.108027
77. Latchaw LA, Nguyen L. Acute appendicitis in diabetic children. Am J Dis Child (1988) 142:1019–20. doi: 10.1001/ARCHPEDI.1988.02150100013001
78. Stewart CL, Wood CL, Bealer JF. Characterization of acute appendicitis in diabetic children. J Pediatr Surg (2014) 49:1719–22. doi: 10.1016/J.JPEDSURG.2014.09.003
79. Roupakias S, Apostolou M-I, Anastasiou A. Acute appendicitis in a diabetic child with salmonella infection. Prague Med Rep (2021) 34:34–8. doi: 10.14712/23362936.2021.4
80. Poddighe D, Sazonov V. Acute acalculous cholecystitis in children. World J Gastroenterol (2018) 24:4870–9. doi: 10.3748/wjg.v24.i43.4870
81. Montelongo-Rodríguez FA, Robles-Torres JI, García-Saucedo J, Ruíz-Galindo E, Pacheco-Molina C, Gómez-Guerra LS. Emphysematous pyelonephritis and emphysematous cholecystitis: A result of uncontrolled type 2 diabetes. Ochsner J (2021) 21:316. doi: 10.31486/TOJ.20.0126
82. Pal K. Laparoscopy in the management of emphysematous cholecystitis and secondary appendicitis in an 11-year-old child with insulin-dependent diabetes mellitus. Afr J Paediatr Surg (2011) 8:211. doi: 10.4103/0189-6725.86065
83. Williams R, Larson NS, Pinsker JE. Occult pyogenic liver abscess in an adolescent with type 2 diabetes. Endocrine (2014) 45:335–6. doi: 10.1007/S12020-013-0036-6/FIGURES/1
84. Kowalewska B, Zorena K, Szmigiero-Kawko M, Wąż P, Myśliwiec M. Higher diversity in fungal species discriminates children with type 1 diabetes mellitus from healthy control. Patient Prefer Adherence (2016) 10:591–9. doi: 10.2147/PPA.S97852
85. Oyom AP, Okello E, Acam V, Aramo C, Mwambi B, Okiria JC, et al. Prevalence and antifungal susceptibility of gastrointestinal candidiasis among diabetic patients: A cross-sectional study. Afr J Lab Med (2020) 9:2225–002. doi: 10.4102/AJLM.V9I1.997
86. Kowalewska B, Kawko M, Zorena K, Myśliwiec M. [Yeast-like fungi in the gastrointestinal tract in children and adolescents with diabetes type 1]. Pediatr Endocrinol Diabetes Metab (2015) 20:170–7. doi: 10.18544/PEDM-20.04.0017
87. Soyucen E, Gulcan A, Aktuglu-Zeybek AC, Onal H, Kiykim E, Aydin A. Differences in the gut microbiota of healthy children and those with type 1 diabetes. Pediatr Int (2014) 56:336–43. doi: 10.1111/PED.12243
88. Olczak-Kowalczyk D, Pyrzak B, Dabkowska M, Pańczyk-Tomaszewska M, Miszkurka G, Rogozińska I, et al. Candida spp. and gingivitis in children with nephrotic syndrome or type 1 diabetes. BMC Oral Health (2015) 15:1–9. doi: 10.1186/S12903-015-0042-6/TABLES/4
89. Atabek ME, Kart H, Erkul I. Prevalence of hepatitis a, b, c and e virus in adolescents with type-1 diabetes mellitus. Int J Adolesc Med Health (2003) 15:133–7. doi: 10.1515/IJAMH.2003.15.2.133/MACHINEREADABLECITATION/RIS
90. Santos MLC, De Brito BB, Da Silva FAF, Sampaio MM, Marques HS, Oliveira E Silva N, et al. Helicobacter pylori infection: Beyond gastric manifestations. World J Gastroenterol (2020) 26:4076–93. doi: 10.3748/WJG.V26.I28.4076
91. Kayar Y, Pamukçu Ö, Eroğlu H, Kalkan Erol K, Ilhan A, Kocaman O. Relationship between helicobacter pylori infections in diabetic patients and inflammations, metabolic syndrome, and complications. Int J Chronic Dis (2015) 2015:1–6. doi: 10.1155/2015/290128
92. Candelli M, Rigante D, Marietti G, Nista EC, Crea F, Bartolozzi F, et al. Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics (2003) 111:800–3. doi: 10.1542/PEDS.111.4.800
93. Bazmamoun H, Rafeey M, Nikpouri M, Ghergherehchi R. Helicobacter pylori infection in children with type 1 diabetes mellitus: A case-control study. J Res Health Sci (2016) 16:68–71. doi: 10.34172/JRHS162565
94. Candelli M, Rigante D, Schiavino A, Gabrielli M, Crea F, Minguell Del Lungo L, et al. High reinfection rate of helicobacter pylori in young type 1 diabetic patients: a three-year follow-up study. Eur Rev Med Pharmacol Sci (2012) 16:1468–72.
95. Khalil T, Dorchy H, Scaillon M, Melot C. [Helicobacter pylori infection and eradication are not related to glycosylated hemoglobin levels (HbA1c) in young patients with type 1 diabetes]. Presse Med (2007) 36:1191–5. doi: 10.1016/J.LPM.2006.12.030
96. Church J, Kainth R, Cifelli P. Helminth infestation complicating diabetic ketoacidosis. Arch Dis Child (2013) 98:872–2. doi: 10.1136/ARCHDISCHILD-2013-304583
97. Oumeish OY. Skin disorders in patients with diabetes. Clin Dermatol (2008) 26:235–42. doi: 10.1016/J.CLINDERMATOL.2007.10.015
98. Baselga Torres E, Torres-Pradilla M. Cutaneous manifestations in children with diabetes mellitus and obesity. Actas Dermosifiliogr (2014) 105:546–57. doi: 10.1016/J.AD.2013.11.014
99. Nino M, Franzese A, Ruggiero Perrino N, Balato N. The effect of obesity on skin disease and epidermal permeability barrier status in children. Pediatr Dermatol (2012) 29:567–70. doi: 10.1111/J.1525-1470.2012.01738.X
100. Berg AK, Olsen BS, Thyssen JP, Zachariae C, Simonsen AB, Pilgaard K, et al. High frequencies of dermatological complications in children using insulin pumps or sensors. Pediatr Diabetes (2018) 19:733–40. doi: 10.1111/PEDI.12652
101. Belmonte MM, Moore DL, Reece ER. Multiple herpetic whitlows in a child performing self-monitoring of blood glucose. Diabetes Care (1986) 9:438–40. doi: 10.2337/DIACARE.9.4.438
102. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol (2003) 149 Suppl 65:1–4. doi: 10.1046/J.1365-2133.149.S65.4.X
103. Pavlović MD, Milenković T, Dinić M, Mišović M, Daković D, Todorović S, et al. The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes Care (2007) 30:1964–7. doi: 10.2337/DC07-0267
104. Kendirci M, Koç AN, Kurtoglu S, Keskin M, Kuyucu T. Vulvovaginal candidiasis in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab (2004) 17:1545–9. doi: 10.1515/JPEM.2004.17.11.1545/MACHINEREADABLECITATION/RIS
105. Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, et al. Prevalence of candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care (2007) 30:312–7. doi: 10.2337/DC06-1469
106. Menne EN, Sonabend RY, Mason EO, Lamberth LB, Hammerman WA, Minard CG, et al. Staphylococcus aureus infections in pediatric patients with diabetes mellitus. J Infect (2012) 65:135–41. doi: 10.1016/J.JINF.2012.04.001
107. Rasli MHM, Zacharin MR. Foot problems and effectiveness of foot care education in children and adolescents with diabetes mellitus. Pediatr Diabetes (2008) 9:602–8. doi: 10.1111/J.1399-5448.2008.00432.X
108. Lombardo F, Passanisi S, Tinti D, Messina MF, Salzano G, Rabbone I. High frequency of dermatological complications in children and adolescents with type 1 diabetes: A web-based survey. J Diabetes Sci Technol (2020) 15:1377–81. doi: 10.1177/1932296820947072
109. Seget S, Rusak E, Partyka M, Samulska E, Pyziak-Skupień A, Kamińska H, et al. Bacterial strains colonizing the sensor electrodes of a continuous glucose monitoring system in children with diabetes. Acta Diabetol (2021) 58:191–5. doi: 10.1007/S00592-020-01601-W/TABLES/1
110. Stevens DL, Bryant AE, Goldstein EJ. Necrotizing soft tissue infections. Infect Dis Clin (2021) 35:135–55. doi: 10.1016/J.IDC.2020.10.004
111. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJC, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis (2005) 41:1373–406. doi: 10.1086/497143
112. Conwell LS, Forrest CR, Allen UD, Perlman K, Daneman D. Necrotizing fasciitis in adolescents with poorly controlled type 1 diabetes mellitus: report of two cases. Pediatr Diabetes (2007) 8:397–400. doi: 10.1111/J.1399-5448.2007.00244.X
113. Shields D, Robinson P, Crowley TP. Iliopsoas abscess – a review and update on the literature. Int J Surg (2012) 10:466–9. doi: 10.1016/J.IJSU.2012.08.016
114. Ladhani S, Phillips SD, Allgrove J. Low back pain at presentation in a newly diagnosed diabetic. Arch Dis Child (2002) 87:543–4. doi: 10.1136/ADC.87.6.543
115. Maines E, Franceschi R, Cauvin V, d’Annunzio G, Prato AP, Castagnola E, et al. Iliopsoas abscess in adolescents with type 1 diabetes mellitus. Clin Case Rep (2015) 3:638–42. doi: 10.1002/CCR3.267
116. Di Coste A, Costantino F, Tarani L, Savastano V, Di Biasi C, Schiavi L, et al. Rhinocerebral zygomycosis with pansinusitis in a 14-year-old girl with type 1 diabetes: A case report and review of the literature. Ital J Pediatr (2013) 39:1–6. doi: 10.1186/1824-7288-39-77/TABLES/1
117. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 54:S23–34. doi: 10.1093/CID/CIR866
118. Ribeiro NFF, Cousin GCS, Wilson GE, Butterworth DM, Woodwards RTM. Lethal invasive mucormycosis: case report and recommendations for treatment. Int J Oral Maxillofac Surg (2001) 30:156–9. doi: 10.1054/ijom.2000.0010
119. Mohammadi R, Meidani M, Mostafavizadeh K, Iraj B, Hamedani P, Mohammad S, et al. Case series of rhinocerebral mucormycosis occurring in diabetic patients. Casp J Intern Med (2015) 6:243.
120. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol (2018) 56:S93–S101. doi: 10.1093/MMY/MYX101
121. Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med Mycol (2018) 56:29–43. doi: 10.1093/MMY/MYX017
122. Manji F, Lam JC, Meatherall BL, Church D, Missaghi B. Severe facial necrosis in a type 1 diabetic patient secondary to mucormycosis masquerading as an internal maxillary artery occlusion: A case report. BMC Infect Dis (2019) 19:1–3. doi: 10.1186/S12879-019-3822-9/FIGURES/2
123. Kumar M, Mishra L, Mohanty R, Nayak R. Diabetes and gum disease: The diabolic duo. Diabetes Metab Syndr Clin Res Rev (2014) 8:255–8. doi: 10.1016/J.DSX.2014.09.022
124. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction *. J Biol Chem (1997) 272:971–6. doi: 10.1074/JBC.272.2.971
125. Hellstein JW, Marek CL. Candidiasis: Red and white manifestations in the oral cavity. Head Neck Pathol 2019 131 (2019) 13:25–32. doi: 10.1007/S12105-019-01004-6
126. Nishimura F, Iwamoto Y, Mineshiba J, Shimizu A, Soga Y, Murayama Y. Periodontal disease and diabetes mellitus: The role of tumor necrosis factor-α in a 2-way relationship. J Periodontol (2003) 74:97–102. doi: 10.1902/JOP.2003.74.1.97
127. Ueta E, Osaki T, Yoneda K, Yamamoto T. Prevalence of diabetes mellitus in odontogenic infections and oral candidiasis: an analysis of neutrophil suppression. J Oral Pathol Med (1993) 22:168–74. doi: 10.1111/J.1600-0714.1993.TB01051.X
128. Gómez-Díaz RA, Ramírez-Soriano E, Tanus Hajj J, Bautista Cruz E, Jiménez Galicia C, Villasis-Keever MA, et al. Association between carotid intima-media thickness, buccodental status, and glycemic control in pediatric type 1 diabetes. Pediatr Diabetes (2012) 13:552–8. doi: 10.1111/J.1399-5448.2012.00868.X
129. Al-Attas SA, Amro SO. Candidal colonization, strain diversity, and antifungal susceptibility among adult diabetic patients. Ann Saudi Med (2010) 30:101–8. doi: 10.4103/0256-4947.60514
Keywords: diabetes mellitus, children, infections, narrative review, adolescence, immunology
Citation: Piccolo G, De Rose EL, Bassi M, Napoli F, Minuto N, Maghnie M, Patti G and d’Annunzio G (2022) Infectious diseases associated with pediatric type 1 diabetes mellitus: A narrative review. Front. Endocrinol. 13:966344. doi: 10.3389/fendo.2022.966344
Received: 10 June 2022; Accepted: 05 August 2022;
Published: 24 August 2022.
Edited by:
Alessandra Fierabracci, Bambino Gesù Children's Hospital (IRCCS), Rome, ItalyReviewed by:
Massimo Maria Trucco, Allegheny General Hospital, Pittsburgh, United StatesRiccardo Schiaffini, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy
Copyright © 2022 Piccolo, De Rose, Bassi, Napoli, Minuto, Maghnie, Patti and d’Annunzio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gianluca Piccolo, giangi.piccolo@gmail.com; Giuseppa Patti, giuseppapatti@gaslini.org